Floatz Rating
B57/100
Confidence
Indicative
Sponsor
Iovance Biotherapeutics, Inc.
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06566092CT.gov Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | — | Active Not Recruiting | — | — | — |
NCT03449108CT.gov LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Soft Tissue Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Lifileucel (this asset) | Iovance Biotherapeutics, Inc. | P2 | B · 57 |
| Palbociclib | Brown University | P2 | BB |
| Nivestim | University of California, Irvine | P3 | BB |
| Cyclophosphamide | St. Jude Children's Research Hospital | P2 | BB |
| Adriamycin | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P3 | BB |
| Dacarbazine | Institut Bergonié | P3 | BB |
| Irinotecan | GI Innovation, Inc. | P1/2 | BB |
| Olaparib | OHSU Knight Cancer Institute | P2 | BB |
| Tislelizumab | Gustave Roussy, Cancer Campus, Grand Paris | P3 | BB |
+42 more in the Soft Tissue Sarcoma cohort
Other indications for Lifileucel
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cutaneous Melanoma | — | P3 | BB · 66 |
| Head And Neck Squamous Cell Carcinoma | — | P2 | B · 58 |
| Metastatic Melanoma | — | P3 | B · 58 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Lifileucel in Soft Tissue Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/lifileucel-soft-tissue-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →